| Description | ABT-255 is a novel 2-pyridone antimicrobial agent for the treatment of tuberculosis. Both drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis showed efficacy in vitro and in vivo. |
| Synonyms | ABT 255, ABT255, UNII-YA04O24J4T |
| molecular weight | 385.43 |
| Molecular formula | C21H24FN3O3 |
| CAS | 186293-38-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Segreti JA, Polakowski JS, Koch KA, Marsh KC, Bauch JL, Rosenberg SH, Sham HL, Cox BF, Reinhart GA. Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol. 2004 Sep;54(3):273-81. Epub 2004 Jun 2. PubMed PMID: 15173957. 2. Tomioka H. [Prospects for development of new antituberculous drugs]. Kekkaku. 2002 Aug;77(8):573-84. Japanese. PubMed PMID: 12235850. 3. Oleksijew A, Meulbroek J, Ewing P, Jarvis K, Mitten M, Paige L, Tovcimak A, Nukkula M, Chu D, Alder JD. In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother. 1998 Oct;42(10):2674-7. PubMed PMID: 9756775; PubMed Central PMCID: PMC105917. |